Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 9/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 8/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5488197 | 0.90 | SMARCA2 (0.42) | SMARCA2SMARCA4CHRNB2CHRNA4GRM4 | |
| SCHEMBL4309817 | 0.90 | SMARCA2 (0.42) | SMARCA2SMARCA4CHRNB2CHRNA4GRM4 | |
| SCHEMBL562935 | 0.78 | S1PR2 (0.47) | SMARCA2SMARCA4CHRNB2CHRNA4SMN1; SMN2 | |
| SCHEMBL6399598 | 0.74 | CTSD (0.48) | SMN1; SMN2CYP3A4ALOX15MAPK1PPARG | |
| SCHEMBL1460401 | 0.74 | ROCK1 (0.58) | SMN1; SMN2KDM4EMEN1LMNAMAPT | |
| SCHEMBL3133040 | 0.73 | KDM4E (0.50) | SMN1; SMN2KDM4EMEN1LMNAMAPT | |
| SCHEMBL7078201 | 0.73 | MAPT (0.49) | MAPK1MEN1LMNAMAPTHTT | |
| SCHEMBL30648816 | 0.72 | HSD17B10 (0.50) | CYP3A4LMNAKMT2ATDP1 | |
| SCHEMBL6201889 | 0.72 | HSD17B10 (0.50) | CYP3A4KDM4EMEN1LMNAMAPT | |
| SCHEMBL7359879 | 0.72 | ALDH1A1 (0.43) | MEN1MAPTKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815895-B2 | Mediators of hedgehog signaling pathways, compositions and uses related hereto | CURIS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815895-B2 | Mediators of hedgehog signaling pathways, compositions and uses related hereto | CURIS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-1807074-B1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120283258-A1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED HERETO | CURIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283258-A1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED HERETO | CURIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-8273890-B2 | Thiophene-imidazopyridines | 4SC AG (DE) | 2012-09-25 | — | — | US | disclosed |
| US-8168653-B2 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168653-B2 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100317660-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | GUICHERIT OIVIN M | 2010-12-16 | — | — | US | disclosed |
| US-20100317660-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | GUICHERIT OIVIN M | 2010-12-16 | — | — | US | disclosed |
| EP-2017277-A1 | Thiophene-imidazopyridines | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-20090012082-A1 | hedgehog genes antagonists such as N-[5-(1H-benzimidazol-2-yl)-6-chloropyridin-3-yl]-2-methyl-6-(trifluoromethyl)pyridine-3-carboxamide, used as anticarcinogenic or antitumor agents | CURIS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012082-A1 | hedgehog genes antagonists such as N-[5-(1H-benzimidazol-2-yl)-6-chloropyridin-3-yl]-2-methyl-6-(trifluoromethyl)pyridine-3-carboxamide, used as anticarcinogenic or antitumor agents | CURIS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2009003911-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2009-01-08 | — | — | WO | disclosed |
| US-7256287-B2 | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256287-B2 | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256287-B2 | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2007-08-14 | — | — | US | disclosed |
| WO-2007047793-A2 | CYCLOPENTENOL NUCLEOSIDE COMPOUNDS, INTERMEDIATES FOR THEIR SYNTHESIS AND METHODS OF TREATING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| CN-1694889-A | Phenyl-aza-benzimidazole compounds for modulating ige and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2005-11-09 | — | — | CN | disclosed |
| US-20040116466-A1 | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317660-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | SHH, SMO, GLI1 | SMARCA2 1967/4885SMARCA4 1957/4885CHRNB2 1844/4885 |
| US-20090012082-A1 | hedgehog genes antagonists such as N-[5-(1H-benzimidazol-2-yl)-6-chloropyridin-3-yl]-2-methyl-6-(trifluoromethyl)pyridine-3-carboxamide, used as anticarcinogenic or antitumor agents | GLI1, SHH, SMO | SMARCA2 1204/4885SMARCA4 1368/4885CHRNB2 2848/4885 |
| US-20120283258-A1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED HERETO | SHH, SMO, GLI1 | SMARCA2 1969/4885SMARCA4 1946/4885CHRNB2 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.